Men's Health

Other pipeline products discussed in this round-up include and advanced renal cell carcinoma agent, a bladder cancer detection agent, and a BPH treatment.

It’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising.

Other products and services discussed in this round-up include a biosimilar for cancer, an American College of Surgeons manual on quality initiatives, a kidney cancer microsite, and more.

Adherence to current guidelines for genetic testing in men with prostate cancer would miss a sizable proportion of patients with pathogenic germline variants, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.

Treatment with radiotherapy plus androgen deprivation therapy may improve survival for select patients who are found to have pathologic node-positive prostate cancer at radical prostatectomy

This article presents an overview of the pathophysiology of varicoceles and discusses indications for treatment, two primary repair techniques, and treatment outcomes.

Heat-free high-velocity waterjet ablation (Aquablation) for BPH performed with an image-guided robot-assisted platform (AquaBeam System) met its primary safety and efficacy endpoints in a phase III study.

Treatment of lower urinary tract symptoms/BPH with convective water vapor ablation (Rezum System) appears to provide significant improvement on two key outcome measures versus medical therapy at up to 2 years, according to a study presented at the AUA annual meeting in Boston.

Information from magnetic resonance imaging and systematic biopsy may be used to identify candidates for partial gland ablation among men with recurrent localized prostate cancer after radiation therapy, researchers from Memorial Sloan Kettering Cancer Center reported at the AUA annual meeting in Boston.

The risk of erectile dysfunction is not increased with the use of a 5-alpha-reductase inhibitor compared with an alpha-blocker for the treatment of BPH.

Early follow-up of men with localized prostate cancer treated with novel technology that integrates fusion biopsy findings to guide high-intensity focused ultrasound (HIFU [Focal One]) shows the technique has promise for minimizing post-treatment morbidity while providing good cancer control, Italian researchers reported at the AUA annual meeting in Boston.

Urologists are no longer the primary initiators of tamsulosin (Flomax) therapy in the United States, suggests an analysis of pharmaceutical claims from more than 50 private health plans.

The development of a model for identifying prostate cancer patients who may be appropriate candidates for hemi-ablative focal therapy remains a work in progress for researchers at Memorial Sloan Kettering Cancer Center.

The following letter was sent to Urology Times in response to a previously published letter to the editor, "Dear USPSTF: Don't discount value of PSA in men 70+."

Other pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.

Authors of a recent study say that long-term therapy with a 5-alpha-reductase inhibitor was associated with increased glucose, increased glycated hemoglobin, and altered lipid profiles.

Despite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study.

These videos each represent a different approach to this complex microsurgical procedure.

"Urology providers and caregivers can serve as the primary venue for positively impacting both the psychological and physical components of men’s health as men trust us with their most intimate and personal issues of life," writes SUNA President Gwendolyn Hooper, PhD, APRN.

Other products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more

Studies of bipolar plasma vaporization of the prostate and thulium vapoenucleation were among the other noteworthy research in BPH/LUTS presented at the AUA annual meeting in Boston.

Transrectal saturation biopsy resulted in higher rates of disease reclassification compared with magnetic resonance (MR) fusion biopsy plus extended sextant prostate biopsy in patients with low-risk prostate cancer on active surveillance.

Maternal postpartum depression (PPD) is a widely studied and discussed phenomenon, whereas much less is known about the concept of paternal PPD. Nonetheless, recent studies have indicated that depression in new fathers is a significant public health concern.

Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.

Findings from a recent study also suggest that obesity may be a factor to consider for men with prostate cancer deciding between active surveillance and definitive treatment.